Biomarin Pharmaceutical - Registered Shares Accounts Payable

As of the most recent data (June 2026), BMRN shows a accounts payable of $1B. That compares with $310M in the prior-year period — up 223.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BMRN's accounts payable is now $1B (was $310M) — a 223.6% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Biomarin Pharmaceutical - Registered Shares is outperforming or lagging.

Tracking BMRN's accounts payable over time shows whether Biomarin Pharmaceutical - Registered Shares is scaling, shrinking, or reshaping that part of the business. The current reading is $1B That compares with $310M in the prior-year period — up 223.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has Biomarin Pharmaceutical - Registered Shares's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $1B) with ownership activity and broader fundamentals.

Biomarin Pharmaceutical - Registered Shares's accounts payable is $1B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.